Telemedicine may take advantage of Supreme Court ruling on med boards

Individual members of state medical boards can be sued for antitrust violations thanks to the Supreme Court’s decision in North Carolina State Board of Dental Examiners v. Federal Trade Commission, which has now led to at least five such suits against health licensing boards across the country, according to POLITICO.

The 2015 ruling said state medical boards could only claim immunity from antitrust suits when the board is actively supervised by state government and its regulation is “a clear expression of state policy.” The Court’s decision was meant to prevent a state board made up of active participants in the market the board regulates, in this case dentists, from using its authority to benefit individual members.

Telehealth companies have begun using this ruling to their advantage in challenging state boards’ regulations. In one example, Dallas-based Teladoc successfully argued to the U.S. District Court for the Western District of Texas that the Texas Medical Board couldn’t require “a face-to-face visit” with a physician before any prescription can be written, a regulation Teladoc argued amounted to a ban on seeing Texas patients.

The Teladoc suit named all 14 members of the board individually, a development which worries groups like the Federation of State Medical Boards.

“This is something that’s certainly going to have a chilling effect on people’s willingness to serve on professional licensing boards because they’re basically volunteers,” Lisa Robin, the group’s chief advocacy officer, said to POLITICO.

The federation had submitted written testimony to Congress about the issues raised in the NC Dental case in February, arguing that since all 50 state medical boards include practicing physicians “it is in the best interest of the public for the medical profession to be regulated by knowledgeable health care professionals who have practical experience in the profession that they are regulating.”

The Court’s decision may be challenged within the Teladoc suit, which is still making its way through federal courts. The Texas board’s deadline to file a brief in the case has been extended several times, POLITICO reported, with the latest due date set for June 2. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.